This study is testing a combination of three drugs – olutasidenib, venetoclax, and azacitidine – for people with newly diagnosed Acute Myeloid Leukemia (AML) that has an IDH1 mutation. Researchers want to see if this combination causes fewer or more side effects, and how well it works compared to standard chemotherapy. You may be eligible if you are between 18 and 75 years old, have an IDH1 mutation, and are able to receive intensive chemotherapy. The study aims to measure how many participants experience too many side effects within 12 months, and how many achieve a complete remission within 3 months. The current status of this study is unclear, and it plans to enroll 16 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 16 participants, and the phase is not specified.

What's involved

You would receive olutasidenib capsules twice daily, venetoclax tablets once daily with a meal, and azacitidine injections or infusions on specific days of each cycle.

Compensation

Not stated in the trial record.

Follow-up

The study will measure excessive toxicity for up to 12 months and complete remission for up to 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.